ApconiX New Year Message 2017!

As we get ready for a busy and exciting 2017, it’s a good time to reflect on ApconiX’s first full year in business and share some notable highlights.

In 2016 we were joined by several additional preclinical experts including Dr Guy Healing, Dr Damian Deavall, Dr Jane Barber, Dr Mike O’Donovan and Dr Peter Ballard taking our group of experts to 14

In March, we celebrated moving into our new offices and ion channel lab in the BioHub at Alderley Park. 

In June, we joined the CIPA consortium – our lab will be providing data to assist in the development and validation of the standardized CIPA protocols. 

We also had a visit from the Rt Hon George Osborne, MP!

By year’s end, our client list has grown from 5 to 45, spanning the UK, Europe and the US.  It’s incredible to think of the progress we have made in such a short period.  The vision of a company that could provide customers with access to a team of dedicated preclinical safety experts with decades of experience and the passion to ensure the right strategies are designed and applied, seems to be bearing fruit. 

We offer dedicated project support, in-licensing due diligence, strategic scientific advice, study monitoring, target safety evaluation and safety-related problem solving.  Our electrophysiology lab provides ion channel screening against a comprehensive range of CIPA ion channels as well as bespoke ion channel development services.

We thank you for your support in 2016 and look forward to working with you in 2017!

By |2018-06-06T14:51:39+00:00January 6th, 2017|Press|Comments Off on ApconiX New Year Message 2017!

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.